Open AccessTherapies on the horizon for cholesterol reduction
Author(s) -
Brown W. Virgil
Publication year - 2001
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960241506
Subject(s) - ezetimibe , medicine , cholesterol , rosuvastatin , sterol o acyltransferase , bile acid , reverse cholesterol transport , statin , pharmacology , cholestyramine , endocrinology , lipoprotein
Summary : Statins are powerful agents for the reduction of low‐density lipoprotein cholesterol (LDL‐C) and reduction of cardiovascular risk. Newly developed statins with increased potency, such as rosuvastatin (Crestor TM ) and NK‐104 (in earlier clinical development), are capable of achieving marked LDL‐C reductions. Cholesterol‐lowering agents with mechanisms of action distinct from those of the statins are in active development. These include bile transport inhibitors. such as improved bile acid‐absorbing resins and specific inhibitors of the ileal Na + /bile acid cotransporter. There are also specific inhibitors of cholesterol absorption, such as ezetimibe, which may provide cholesterol lowering that is additive to that achieved with statin treatment. Another approach is to reduce cardiovascular risk by modifying atherosclerotic processes within the arterial wall, as represented by the acyl CoA:cholesterol acyltransferase (ACAT) inhibitor avasimibe; ACAT inhibitors may reduce atherosclerotic lesions by inhibiting macrophage cholesterol storage.